Search research articles
Contact Us
Filters
Showing results (41-50 of 59) with videos related to
Page
of 6
Sort By:
Clinical Pharmacology in Drug Development
|
June 21, 2019
Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
Daryl J Fediuk, Kyle Matschke, Yali Liang, et al.
Diabetes, Obesity & Metabolism
|
March 5, 2019
Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
Linong Ji, Yanmei Liu, Heng Miao, et al.
Diabetes, Obesity & Metabolism
|
December 22, 2017
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
Richard E Pratley, Roy Eldor, Annaswamy Raji, et al.
Diabetes, Obesity & Metabolism
|
September 19, 2017
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study
Samuel Dagogo-Jack, Jie Liu, Roy Eldor, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
March 4, 2017
Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome
Jennifer Q Dong, James R Gosset, Odette A Fahmi, et al.
Diabetologia
|
April 3, 2020
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
David Z I Cherney, Hiddo J L Heerspink, Robert Frederich, et al.
American Heart Journal
|
October 6, 2018
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Christopher P Cannon, Darren K McGuire, Richard Pratley, et al.
JAMA Cardiology
|
October 8, 2020
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis
Darren K McGuire, Weichung J Shih, Francesco Cosentino, et al.
Pharmacogenetics and Genomics
|
May 3, 2005
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy
Steven G Terra, Karen K Hamilton, Daniel F Pauly, et al.
Circulation
|
October 7, 2020
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
Francesco Cosentino, Christopher P Cannon, David Z I Cherney, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 59) with videos related to
Sort By:
Page
of 6
Clinical Pharmacology in Drug Development
|
June 21, 2019
Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
Daryl J Fediuk, Kyle Matschke, Yali Liang, et al.
Diabetes, Obesity & Metabolism
|
March 5, 2019
Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
Linong Ji, Yanmei Liu, Heng Miao, et al.
Diabetes, Obesity & Metabolism
|
December 22, 2017
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
Richard E Pratley, Roy Eldor, Annaswamy Raji, et al.
Diabetes, Obesity & Metabolism
|
September 19, 2017
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study
Samuel Dagogo-Jack, Jie Liu, Roy Eldor, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
March 4, 2017
Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome
Jennifer Q Dong, James R Gosset, Odette A Fahmi, et al.
Diabetologia
|
April 3, 2020
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
David Z I Cherney, Hiddo J L Heerspink, Robert Frederich, et al.
American Heart Journal
|
October 6, 2018
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Christopher P Cannon, Darren K McGuire, Richard Pratley, et al.
JAMA Cardiology
|
October 8, 2020
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis
Darren K McGuire, Weichung J Shih, Francesco Cosentino, et al.
Pharmacogenetics and Genomics
|
May 3, 2005
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy
Steven G Terra, Karen K Hamilton, Daniel F Pauly, et al.
Circulation
|
October 7, 2020
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
Francesco Cosentino, Christopher P Cannon, David Z I Cherney, et al.
Page
of 6